Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses
- PMID: 27852697
- DOI: 10.1158/1078-0432.CCR-16-1078
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses
Abstract
Purpose: Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy-number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass.Experimental Design: We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing.Results: Patterns of chromosomal instability were detectable in cell-free DNA using 44 healthy individuals as a reference. Profiles were representative of those observed in matching tumor tissue and contained CNAs enriched in two large datasets of high-grade serous ovarian cancer (HGSOC). Quantitative measures of chromosomal instability, referred to as genome-wide z-scores, were significantly higher in patients with ovarian carcinoma than in healthy individuals or patients with benign disease. Cell-free DNA testing improved malignancy detection (AUC 0.89) over serum CA-125 (AUC 0.78) or the risk of malignancy index (RMI, AUC 0.81). AUC values of cell-free DNA testing even further increased for HGSOC patients specifically (AUC 0.94). At a specificity of 99.6%, a theoretical threshold required for ovarian cancer screening, sensitivity of cell-free DNA testing was 2- to 5-fold higher compared with CA-125 and RMI testing.Conclusions: This is the first study evaluating the potential of cell-free DNA for the diagnosis of primary ovarian cancer using chromosomal instability as a read-out. We present a promising method to increase specificity of presurgical prediction of malignancy in patients with adnexal masses. Clin Cancer Res; 23(9); 2223-31. ©2016 AACR.
©2016 American Association for Cancer Research.
Similar articles
-
Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.Ultrasound Obstet Gynecol. 2019 Dec;54(6):815-822. doi: 10.1002/uog.20363. Epub 2019 Nov 11. Ultrasound Obstet Gynecol. 2019. PMID: 31152572
-
An improved risk of malignancy index in diagnosis of adnexal mass.Chin Med J (Engl). 2012 Feb;125(3):533-5. Chin Med J (Engl). 2012. PMID: 22490416
-
Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.Gynecol Oncol. 2018 Aug;150(2):318-323. doi: 10.1016/j.ygyno.2018.06.004. Epub 2018 Jun 19. Gynecol Oncol. 2018. PMID: 29929922
-
CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.Int J Biol Markers. 2015 Nov 11;30(4):e394-400. doi: 10.5301/jbm.5000158. Int J Biol Markers. 2015. PMID: 26109367 Review.
-
CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.Int J Biol Markers. 2015 Jul 22;30(3):e333-40. doi: 10.5301/jbm.5000139. Int J Biol Markers. 2015. PMID: 25704505 Review.
Cited by
-
Utility of Circulating Cell-Free DNA in Assessing Microsatellite Instability and Loss of Heterozygosity in Breast Cancer Using Human Identification Approach.Genes (Basel). 2022 Mar 25;13(4):590. doi: 10.3390/genes13040590. Genes (Basel). 2022. PMID: 35456396 Free PMC article.
-
High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.Genome Med. 2021 Jul 9;13(1):111. doi: 10.1186/s13073-021-00922-x. Genome Med. 2021. PMID: 34238352 Free PMC article.
-
High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.Biomedicines. 2024 Jan 19;12(1):229. doi: 10.3390/biomedicines12010229. Biomedicines. 2024. PMID: 38275400 Free PMC article. Review.
-
Non-invasive Technology Advances in Cancer-A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers.Front Digit Health. 2020 Dec 11;2:573010. doi: 10.3389/fdgth.2020.573010. eCollection 2020. Front Digit Health. 2020. PMID: 34713045 Free PMC article. Review.
-
Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.Onco Targets Ther. 2019 Dec 27;12:11517-11530. doi: 10.2147/OTT.S227156. eCollection 2019. Onco Targets Ther. 2019. PMID: 31920340 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous